Shareholders who lost money in American Depositary Receipts of Endava plc (NYSE: DAVA) should contact Wolf Haldenstein Immediately

Endava ADRs fell $0.68, or 24.37%, to $2.11 on September 22, 2026, after the company disclosed that CFO Mark Thurston was placed on administrative leave pending an independent investigation into accounting treatment of certain customer and supplier agreements. A securities class-action complaint alleges investors were misled about the accounting review, delayed Q4 and full-year 2026 results, and the effectiveness of internal controls; these are allegations, not established findings. The lead-plaintiff deadline is November 30, 2026.

Analysis

The lawsuit notice is a weak new signal: it is a plaintiff-firm solicitation, and its allegations are not findings. The more consequential issue is the underlying audit-driven review. Until the company clarifies scope and timing, investors cannot reliably underwrite reported revenue, controls, or the quality of cash conversion. For a technology-services business, prolonged uncertainty can also become commercial: procurement teams may defer awards or tighten diligence, while employee retention and hiring become harder. Those effects could matter more than eventual litigation costs, but they remain conditional—not established by this notice.

The immediate repricing described in the article has already occurred; without a current quote, liquidity, or options data, chasing a short is not justified. Over the next 1–3 months, the key catalysts are a credible investigation update, financial-result timing, and auditor conclusions—not the lead-plaintiff deadline itself. Over 6–18 months, a restatement or control weakness could raise financing, customer-confidence, and valuation risks; a bounded review with timely, audited reporting could support a sharp recovery. Watch EPAM Systems, Globant, and Accenture only as potential relative beneficiaries if clients redirect work; there is no evidence here of actual share gains. The contrarian point is that the legal headline may be mostly noise, but treating the accounting review as routine could underprice a broader reporting and customer-retention problem.

Key Decisions for Investors

• For existing DAVA exposure, keep risk limits tight and avoid averaging down until the company gives a verifiable scope and timetable for the review and restores reliable reporting. Treat any revised results, auditor qualification/resignation, or material-control disclosure as a thesis escalation.
• Do not initiate a fresh outright short solely on this notice after the reported sharp selloff. Reassess after the next company update; a deterioration in reporting or guidance would improve the catalyst case, while a bounded review and on-time audited results would invalidate it.
• Set an alert for the next 1–3 months on results timing, any restatement or control finding, and evidence of customer or booking deterioration. Track cash conversion and receivables alongside revenue: persistent divergence would indicate that the risk is extending beyond accounting presentation.
• If seeking event exposure, consider a defined-risk DAVA put spread only after checking current option liquidity and implied volatility; avoid paying an excessive volatility premium. The November 30 lead-plaintiff deadline is not, by itself, a fundamental catalyst.